2000
|
||
|---|---|---|
|
January
January; 45 (1): 1 - 135 |
February
February; 45 (2): 137 - 266 Supplement: Tonsillopharyngitis revisited |
March
March; 45 (3): 267 - 415 Supplement: Optimizing outcomes in the management of acute exacerbations of chronic bronchitis |
|
April
April; 45 (4): 417 - 556 Supplement: Gemifloxacin:potency and performance Supplement: Recent advances in the management of herpesvirus infections |
May
May; 45 (5): 557 - 717 |
June
June; 45 (6): 719 - 934 |
|
July
July; 46 (1): 1 - 155 Supplement: Evolving quinolone therapy: focus on gemifloxacin |
August
August; 46 (2): 157 - 345 Supplement: Progress in the management of urinary tract infections Supplement: Global trends in resistance: initial results from the MYSTIC longitudinal surveillance programme |
September
September; 46 (3): 347 - 522 |
|
October
October; 46 (4): 523 - 649 |
November
November; 46 (5): 651 - 867 |
December
December; 46 (6): 869 - 1052 |